結果

結果と考察のセクションは1つにまとめてもいいですし、別々に示しても構いません。短くわかりやすい見出しを付けて細分化することもできます。

  • 「方法」のセクションと同様、異なる実験の結果を区別するために小見出しを用いる。
  • 結果は論理的な順序で提示する。重要性の順序で示すのが一般的で、必ずしも実験が実施された順序に示すわけではない。結果の記述には過去形を用いる。ただし、図表の説明には現在形を用いる。
  • 図表および本文の中で同じデータを繰り返さないようにする。図表データのほとんどを論文本文でも示すのはよくある間違いである。本文では図表から読み取れる内容を要約するか、最も重要なデータを1つか2つ示すのみにする。文章よりも図表のほうがデータは読み取りやすい。
  • 本文中に統計解析の結果を示す。通常、統計学的に有意な差が示されたときはp値を提示する。

Example

Source

Hitesh N Appaiah, Chirayu P Goswami, Lida A Mina, Sunil Badve, George W Sledge, Yunlong Liu and Harikrishna Nakshatri. Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. Breast Cancer Research, 2011 Sep 13;13(5):R86. Publisher full text

Results

miRNA and small RNA expression analyses

Earlier studies showing the presence of miR-21 and miR-155 in the serum/plasma of patients with cancer [25,26] prompted us to evaluate their levels in the sera of healthy subjects and patients with breast cancer. U6, 5S, miR-16, RNU66, RNU49, RNU19, and SNORD44 levels were also analyzed in these samples to identify a small RNA expressed at a similar level in equal volume of sera from both healthy subjects and patients with cancer to serve as a normalization control. Among these, miR-16 has previously been used as a normalization control for serum miRNA profiling studies [25]. RNU66, RNU48, and RNU19 were undetectable. miR-16 is one of the most abundant miRNAs in the serum (average cycle threshold (CT) of 24) compared with any other RNA analyzed, and the abundance of this miRNA in the serum was similar between healthy subjects and patients with cancer (Table 4 and Figure 1a)...

Serum U6 and 5S in relation to ER/PR and nodal status of primary tumors

We next determined whether the upregulation of U6 and 5S observed above is unique to specific subtypes of breast cancer. ER/PR status of 36 tumors, out of 39 patient samples used in the study, was known; 24 and 12 were ER/PR+ and ER/PR-, respectively. In this subgroup analysis, U6, but not 5S, levels were higher in the sera of patients with ER/PR+ breast cancer compared with healthy subjects with or without normalization with miR-16 and SNORD44 (Table 5 and Figure 3). Despite a small sample size, sera of patients with ER/PR- demonstrated elevated U6 and 5S levels compared with healthy subjects when miR-16 or SNORD44 was used as an internal control (Table 5 and Figure 3). miR-21 level was similar between healthy subjects and patients with cancer of either subtype. Note that the differences in the levels of these RNAs between ER/PR+ and ER/PR- were not statistically significant (data not shown)...

U6 levels are elevated in sera of patients with breast cancer, irrespective of metastasis

We collected sera from 15 healthy subjects, 15 clinically disease-free patients with breast cancer, and 15 patients with stage IV metastatic disease. RNA from the three groups (cohort 2) was prepared at the same time from an equal volume of sera. The cDNA was prepared with 25 ng of RNA and analyzed for the levels of U6, 5S, miR-21, and miR-16. In this cohort, as with the first cohort, U6 level was significantly elevated in the sera of clinically disease-free patients with breast cancer without normalization (Table 6 and Figure 4) (5.35-fold, P = 3.09 x 10-5) or with normalization with SNORD44 (6.6-fold, P = 0.00028)...

英語には「1枚の絵は1000の言葉に値する(A picture is worth a thousand words)」という有名なことわざがあります。これは、文章よりも1つの絵の方が結果ははるかによく伝わるということです。ですから、論文を書くときには図表を上手く利用しましょう!ただし、冗長な図表の使用(例:形式は異なるが同じ内容を示す図を2つ作成)や、本文で情報を示したほうが良い場合に図表を使う(例:図や表にするには十分なデータがない場合)ことはやめましょう

Submit a manuscript Sign up for article alerts